tailieunhanh - Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells

Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. | Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells

TỪ KHÓA LIÊN QUAN